BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s stock price traded down 3.8% during trading on Tuesday . The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Performance
The firm has a market cap of C$168.68 million and a P/E ratio of -28.19. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average is C$10.60 and its two-hundred day moving average is C$10.60.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- A month before the crash
- You Still Think Silver’s a Joke? Watch What Happens Next.
- The $100 Trillion AI Story No One Is Telling You
- S&P 8000
- How a Family Trust May Be Able To Help Preserve Your Wealth
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
